Trial | NCT00262275  Report issue

Title

Optimum Platelet Inhibition After Coronary Bypass Surgery
Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    None
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.
Study Started
Jul 31
2002
Primary Completion
Jul 31
2004
Last Update
Jan 22
2016
Estimate

Drug Aspirin, Clopidogrel

Criteria 

Inclusion Criteria:

We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.

Exclusion Criteria:

Preoperative exclusion criteria:

patients who are have not stopped aspirin 7 days prior to surgery
patients on concomitant NSAIDS
patients with a previous history platelet disorders, splenectomy or haematological disorders
patients with aspirin induced asthma
patients with any contraindications to aspirin (GI bleed)
patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
Women of childbearing potential
Patients of less than 18 years
If informed consent cannot be obtained
If for any reason the consultant surgeon or anaesthetist deems it to be appropriate

Operative exclusion criteria:

• Concomitant procedures

Postoperative exclusion criteria:

patients who receive platelet transfusion
patients who receive NSAIDS
requirement for intra aortic balloon pump support
failure of extubation within 24 hours
No Results Posted